Using engineered macrophages to clear harmful proteins in Alzheimer's disease
Amyloid Beta CAR Macrophages: a cell engineering strategy to clear pathogenic proteins
This study is exploring a new way to help people with Alzheimer's by using specially designed immune cells to better clear harmful proteins from the brain, which could lead to improved treatments for the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11010782 on NIH RePORTER |
What this research studies
This research focuses on developing a new approach to help clear amyloid beta proteins, which are linked to Alzheimer's disease, using specially engineered macrophages. These immune cells are designed to target and remove the amyloid beta proteins more effectively than current treatments. The study aims to understand how these engineered macrophages interact with amyloid beta in the brain and whether they can reduce inflammation associated with Alzheimer's. By improving the way the brain clears these harmful proteins, the research hopes to provide a more effective treatment option for patients with Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk for developing the condition.
Not a fit: Patients with other forms of dementia unrelated to amyloid beta pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel therapy that significantly improves the clearance of amyloid beta proteins in Alzheimer's patients, potentially slowing disease progression.
How similar studies have performed: While there have been various approaches to targeting amyloid beta, this specific method using engineered macrophages is novel and has not been extensively tested in clinical settings.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Gill, Saar — University of Pennsylvania
- Study coordinator: Gill, Saar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.